Tags

Type your tag names separated by a space and hit enter

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Thromb Res. 2006; 117(5):487-92.TR

Abstract

BACKGROUND

The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer.

MATERIAL AND METHODS

We studied 104 women with breast carcinoma (patient group) and 104 healthy age-matched women (control group). In patients and controls, the PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA.

RESULTS

The frequency of the PAI-1 4G allele tended to be higher in patients than in controls (p=0.062). The presence of the 4G allele (4G/5G plus 4G/4G genotypes) was significantly higher among patients with histological grade 3 tumors than among those with grade 1 tumors (p=0.026). Furthermore, patients with the 4G/4G genotype had significantly higher tissue PAI-1 levels than those with the 5G/5G genotype. Moreover, tissue PAI-1 antigen levels were significantly and positively correlated with tumor severity (p=0.003) and tumor size (p=0.009). However, no significant differences in PAI-1 level were observed in relation to menopause, hormone receptor or nodal status.

CONCLUSION

Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer.

Authors+Show Affiliations

Castelló R
Hospital Universitario La Fe, Centro de Investigación. Avda. Campanar 21, 46009 Valencia, Spain.
España F
No affiliation info available
Vázquez C
No affiliation info available
Fuster C
No affiliation info available
Almenar SM
No affiliation info available
Aznar J
No affiliation info available
Estellés A
No affiliation info available

MeSH

AdultAgedAged, 80 and overAllelesBreast NeoplasmsEnzyme-Linked Immunosorbent AssayFemaleGenotypeHumansMiddle AgedPlasminogen Activator Inhibitor 1Polymorphism, GeneticPrognosisReverse Transcriptase Polymerase Chain ReactionSeverity of Illness Index

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15907980

Citation

Castelló, Remedios, et al. "Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Breast Cancer Patients and Its Association With Tissue PAI-1 Levels and Tumor Severity." Thrombosis Research, vol. 117, no. 5, 2006, pp. 487-92.
Castelló R, España F, Vázquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117(5):487-92.
Castelló, R., España, F., Vázquez, C., Fuster, C., Almenar, S. M., Aznar, J., & Estellés, A. (2006). Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thrombosis Research, 117(5), 487-92.
Castelló R, et al. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Breast Cancer Patients and Its Association With Tissue PAI-1 Levels and Tumor Severity. Thromb Res. 2006;117(5):487-92. PubMed PMID: 15907980.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. AU - Castelló,Remedios, AU - España,Francisco, AU - Vázquez,Carlos, AU - Fuster,Carlos, AU - Almenar,Sergio M, AU - Aznar,Justo, AU - Estellés,Amparo, PY - 2005/02/21/received PY - 2005/03/21/revised PY - 2005/03/22/accepted PY - 2005/5/24/pubmed PY - 2006/9/20/medline PY - 2005/5/24/entrez SP - 487 EP - 92 JF - Thrombosis research JO - Thromb Res VL - 117 IS - 5 N2 - BACKGROUND: The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer. MATERIAL AND METHODS: We studied 104 women with breast carcinoma (patient group) and 104 healthy age-matched women (control group). In patients and controls, the PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA. RESULTS: The frequency of the PAI-1 4G allele tended to be higher in patients than in controls (p=0.062). The presence of the 4G allele (4G/5G plus 4G/4G genotypes) was significantly higher among patients with histological grade 3 tumors than among those with grade 1 tumors (p=0.026). Furthermore, patients with the 4G/4G genotype had significantly higher tissue PAI-1 levels than those with the 5G/5G genotype. Moreover, tissue PAI-1 antigen levels were significantly and positively correlated with tumor severity (p=0.003) and tumor size (p=0.009). However, no significant differences in PAI-1 level were observed in relation to menopause, hormone receptor or nodal status. CONCLUSION: Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer. SN - 0049-3848 UR - https://www.unboundmedicine.com/medline/citation/15907980/Plasminogen_activator_inhibitor_1_4G/5G_polymorphism_in_breast_cancer_patients_and_its_association_with_tissue_PAI_1_levels_and_tumor_severity_ DB - PRIME DP - Unbound Medicine ER -